• Japanese
  • Korean
  • Chinese
Cover Image

Clinical trials in Central Europe 2012: Development forecasts for 2012-2014

  • Published:
  • 193 Pages
  • PMR

Abstract

Product description

image1

The report analyses the environment for conducting clinical trials in Poland, Hungary, the Czech Republic, Romania, Slovakia and Bulgaria. It presents key information regarding market size in terms of the number of clinical trials and size of market share of the largest sponsors.

It also covers the most influential trends and circumstances affecting the sector and present-day market value, along with forecasts for 2012-2014 based on the number of newly registered clinical trials. It contains detailed coverage of current and anticipated market conditions, opportunities and obstacles to overall market growth, length of the average registration time for clinical trials, attributes and market standing of the major companies conducting clinical trials, the largest players (sponsors and CROs, their activity in the area of clinical trials, with special attention given to the number of trials, location, and therapeutic areas).

The report also features a comparative analysis of market, governmental and regulatory conditions governing the conduct of clinical trials in the analysed CE countries.

Why learn more about this market?

This region is very attractive to pharmaceutical companies and there are many conferences and a great deal of activity and interest in the subject of clinical trials. Companies are searching urgently for new areas in which to establish and conduct trials, as in the developed countries, the recruitment rate is very slow. Timing is important, since companies are now under increasing pressure to develop new therapies as patents on many blockbuster drugs have expired or will expire in the near future.

Key information contained in this report:

  • Size of the clinical trials market in CE (as determined by number of trials) with forecasts for 2012-2014 and breakdowns for individual countries. It includes major trends and circumstances that have affected the development of the sector in the last couple of years.
  • The current market situation, opportunities for and obstacles to its further development
  • The average registration time for clinical trials

" Comparative analysis of conditions under which clinical trials are conducted in CE Legal aspects of the sector, including information on the upcoming legislative modifications that are relevant to the conduct of Clinical Trials Detailed profiles of the largest CROs and trial sponsors active in the region.

Questions answered by this report:

  • Which countries are the best and worst choices in which to conduct a clinical trial?
  • What are the specific conditions, benefits and drawbacks of conducting clinical trials in Poland, Hungary, the Czech Republic, Romania, Slovakia and Bulgaria?
  • Which are the most active sponsors in the region, what types of drugs are currently being tested, and which trial phases are being conducted?
  • Which are the largest and most influential CROs in the region?
  • What is the average time to register a clinical trial in Central European countries?
  • Which countries are noted for delays during the registration of a clinical trial?
  • Which legal regulations have the most profound effects on clinical trials?

Unique information provides added value

With unique coverage and analysis of market conditions in each of the covered countries, careful analysis of relationships between trends and results, solid, explanatory forecasts and in depth profiles of the market's most experienced and successful players, this comprehensive report surpasses all competition in terms of value.

Companies mentioned in this report:

Roche, Pfizer, Novartis, GlaxoSmithKline, Eli Lilly, Bristol-Myers Squibb, AstraZeneca, Johnson and Johnson, Boehringer Ingelheim, Amgen, Total, Quintiles, Covance, Icon, Parexel, Premier Research, INC Research, PRA, PPD, PSI, Monipol.

This report is an essential business resource:

  • When beginning operations in the CE clinical trials market
  • When expanding into the clinical trials market in new countries
  • When effecting a merger or acquisition
  • When developing a strategy for success in this marketplace
  • When analysing the potential of this marketplace
  • When monitoring activity in this market
  • When estimating the market share of a specific company
  • When preparing forecasts regarding the number of upcoming clinical trials
  • When preparing in-house analyses for management and/or shareholders.

This report is targeted to the needs of:

  • Pharmaceutical manufacturers - sponsors of clinical drug trials
  • Companies that are in the business of conducting clinical trials - CRO, SMO
  • Companies engaged in producing innovative pharmaceuticals
  • Firms specializing in consulting, research and analysis
  • Government institutions, embassies, universities and research institutes
  • Chambers of commerce, trade and industry organisations
  • Financial institutions: banks, brokerage houses, investment funds
  • Creators of global databases.

Extract from this report

  • Barriers to conducting clinical trials in Central Europe are mainly administrative hurdles often encountered by market players operating in emerging countries, such as time delays in completing administrative procedures or difficulties connected with logistics. Cultural differences may also cause interference and difficulty.
  • The global economic crisis has adversely affected the number of clinical trials held in all countries analysed by this report. Regionally, in 2009, the decline in the number of trials was nearly 5% compared to 2008. In 2010, the entire CE market recovered, posting a 4% higher level of approved trials than in 2009. As our estimates showed, 2011 ended with a slightly lower growth dynamic than 2010, attributed mostly to a decrease in the number of trials in Hungary due to legal changes.

Market commentary by expert

In the area of clinical trials, the Central European region provides unique advantages to international pharmaceutical concerns: the associated costs of trials remain relatively low, it is easier to find appropriate candidates to participate in a clinical trial, as candidates are more interested in participation due to lack of money and limited reimbursement. The region analysed still participates in a centralised healthcare system, which means that its countries contain large hospitals that specialise in oncology, cardiology and rheumatology, which rank among the most popular therapeutic categories for clinical trials. Worthy of note, however, are the drawbacks and barriers described by the report as they represent crucial knowledge for any company conducting (or intending to commence) clinical trials in the six countries analysed in the publication.

Monika Stefańczyk, Head Pharmaceutical market Analyst

Table of Contents

Methodology

Executive summary

Size of the clinical trial market in CE between 2004 and 2014

  • Main trends and events in the clinical trials segment
    • Overview of trends and events in CE
    • Poland
    • Hungary
    • Czech Republic
    • Romania
    • Bulgaria
    • Slovakia
  • Number of clinical trials conducted in CE
  • Phases of clinical trial conducted in CE
  • Categories of drugs under investigation in CE
  • Share of CE in the clinical trials conducted worldwide
  • Poland
    • Number of clinical trials
    • Phases
    • Therapeutic categories
  • Hungary
    • Number of clinical trials
    • Phases
    • Therapeutic categories
  • Czech Republic
    • Number of clinical trials
    • Phases
    • Therapeutic categories
  • Romania
    • Number of clinical trials
    • Phases
    • Therapeutic categories
  • Bulgaria
    • Number of clinical trials
    • Phases
    • Therapeutic categories
  • Slovakia
    • Number of clinical trials
    • Phases
    • Therapeutic categories

Comparative analysis of clinical research environment in selected CE countries

  • Legislation
  • Ethics committees
  • Registration of clinical trials
  • Number of clinical sites
  • Patient recruitment
  • Quality
    • CRF quality
  • Cost of clinical trials
  • General comparison
  • Inspections of clinical trials
    • Poland
    • Hungary
    • Czech Republic
    • Romania
    • Bulgaria
  • Slovakia

Analysis of clinical trials conducted by international concerns

  • Roche
    • Number of trials conducted
    • Clinical trial phases
    • Therapeutic categories
    • R&D spending
  • Pfizer
    • Number of trials conducted
    • Clinical trial phases
    • Therapeutic categories
    • R&D spending
    • Important events
  • GlaxoSmithKline
    • Number of trials conducted
    • Clinical trial phases
    • Therapeutic categories
    • R&D spending
    • Important events
  • Novartis
    • Number of trials conducted
    • Clinical trial phases
    • Therapeutic categories
    • R&D spending
  • Eli Lilly
    • Number of trials conducted
    • Clinical trial phases
    • Therapeutic categories
    • R&D spending
  • Bristol-Myers Squibb
    • Number of trials conducted
    • Clinical trial phases
    • Therapeutic categories
    • R&D spending
  • AstraZeneca
    • Number of trials conducted
    • Clinical trial phases
    • Therapeutic categories
    • R&D spending
    • Important events
  • Johnson & Johnson
    • Number of trials conducted
    • Clinical trial phases
    • Therapeutic categories
    • R&D spending
  • Boehringer Ingelheim
    • Number of trials conducted
    • Clinical trial phases
    • Therapeutic categories
    • R&D spending
    • Important events
  • Amgen
    • Number of trials conducted
    • Clinical trial phases
    • Therapeutic categories
    • R&D spending

Profiles of selected CROs operating in the CE market

  • International CROs
    • Quintiles
    • Covance
    • PPD
    • Icon
    • Parexel
    • INC Research
    • PRA
    • ClinTec International
    • Premier Research
    • PSI (PSI Pharma Support)
    • Altiora
    • GCT Trials
  • Local CROs
    • Bulgaria
      • Pro-Val
      • Convex
    • Czech Republic
      • Axon CRO
      • East Health Outcomes Research Network
      • Leading Clinical Research
      • Phamos Central & Eastern Europe
    • Hungary
      • HungaroTrial
      • BiTrial CRO
      • Argint International
      • Trial Masters
    • Poland
      • KCR
      • Monipol
      • Romania
      • Cebis International
      • Rotrial
      • Standard Medical Product
    • Slovakia
      • L&V Research Services
      • PanoniaTrial
      • Syncro Clinical Research

Assessment of CE potential as a site for clinical trials

  • Corruption
  • Demographic trends
  • Epidemiological trends and the most frequent causes of death
    • Circulatory system diseases
    • Cancer
      • Trachea, bronchus and lung cancer
      • Breast cancer
    • Respiratory system diseases
    • Digestive system diseases
    • Diabetes
    • Blood and blood-forming organs diseases
    • Mental disorders
    • Genitourinary system diseases
  • Medical personnel
  • Healthcare establishments
    • Number of hospitals
    • Number of beds

Legislative environment

  • Poland
    • Key legislation and institutions regulating clinical research
    • Obtainment of clinical trials licence
      • Applying to commence clinical trials
      • Charges for filing applications for clinical trial registration
      • Duration of application processing
      • Refusal to issue a licence
      • Applications to the ethics committee
      • Fees for clinical trial opinions
    • Insurance in clinical trials
    • Personal data protection in clinical trials
    • Clinical trials with minors
    • Planned legislative changes
  • Hungary
    • Key legislation and institutions regulating clinical research
    • Obtainment of clinical trials licence
      • Applying to commence clinical trials
      • Charges for filing applications for clinical trial registration
      • Duration of application processing
      • Applications to the ethics committee
    • Insurance in clinical trials
    • Clinical trials with minors
  • Czech Republic
    • Key legislation and institutions regulating clinical research
    • Obtainment of clinical trials licence
      • Applying to commence clinical trials
      • Charges for filing applications for clinical trial registration
      • Duration of application processing
      • Applications to the ethics committee
      • Fees for opinions of ethics committees
    • Insurance in clinical trials
    • Personal data protection in clinical trials
    • Clinical trials with minors
  • Romania
    • Key legislation and institutions regulating clinical research
    • Obtainment of clinical trials licence
      • Applying to commence clinical trials
      • Charges for filing applications for clinical trial registration
      • Duration of application processing
      • Applications to the ethics committee
      • Fees for clinical trial opinions
      • Refusal to issue a licence
    • Insurance in clinical trials
    • Clinical trials with minors
    • Planned legislative changes
  • Bulgaria
    • Key legislation and institutions regulating clinical research
    • Obtainment of clinical trials licence
      • Applying to commence clinical trials
      • Charges for filing applications for clinical trial registration
      • Duration of application processing
      • Applications to the ethics committee
      • Fees for clinical trial opinions
    • Insurance in clinical trials
    • Personal data protection in clinical trials
    • Clinical trials with minors
  • Slovakia
    • Key legislation and institutions regulating clinical research
    • Obtainment of clinical trials licence
      • Applying to commence clinical trials
      • Charges for filing applications for clinical trial registration
      • Duration of application processing
      • Applications to the ethics committee
      • Fees for clinical trial opinions
      • Duration of application processing
    • Clinical trials with minors

List of graphs

List of tables

About PMR

Contact PMR

List of graphs

  • Number of clinical trials in CE countries analysed and change (%), 2008-2014
  • Share of individual countries in total CE region, by number of newly registered clinical trials, 2011 and 2014
  • CAGR for countries analysed, by number of newly registered clinical trials, 2012-2014
  • Regions where biotech and pharma staff would invest most heavily if they ran a global CRO (%), H1 and H2 2011
  • R&D investment value of top 10 EU Scoreboard pharmaceutical companies and leading EU Scoreboard pharmaceutical companies in CEE (€ m), 2010
  • CEE Scoreboard pharmaceutical companies by R&D to net sales ratio (%), 2009 and 2010
  • Top 10 EU Scoreboard pharmaceutical companies and leading CEE Scoreboard pharmaceutical companies by R&D to net sales ratio (%), 2010
  • Number of clinical trials in CE countries analysed and change (%), 2008-2014
  • Breakdown of open clinical trials in CE countries analysed (%), March 2012
  • Number of open clinical trials in CE, by therapeutic category, as of March 2012
  • Share of CE countries analysed in global number of clinical trials (%), 2005-2010
  • Number of new clinical trials registered in Poland and change (%), 1994-2014
  • Breakdown of open clinical trials in Poland (%), by phase, as of March 2012
  • Number of open clinical trials in Poland (%), by therapeutic category, as of March 2012
  • Number of new clinical trials registered in Hungary and change (%), 2005-2014
  • Breakdown of open clinical trials in Hungary (%), by phase, as of March 2012
  • Number of open clinical trials in Hungary (%), by therapeutic category, as of March 2012
  • Number of new clinical trials registered in the Czech Republic and change (%), 2005-2014
  • Breakdown of open clinical trials in the Czech Republic (%), by phase, as of March 2012
  • Number of clinical trials authorised in the Czech Republic (%), by therapeutic category, 2000-2011
  • Number of open clinical trials in the Czech Republic (%), by therapeutic category, as of March 2012
  • Number of new clinical trials registered in Romania and change (%), 2008-2014
  • Breakdown of open clinical trials in Romania (%), by phase, as of March 20121
  • Number of new clinical trials registered in Romania, by phase, 2008 and 2009
  • Number of open clinical trials in Romania, by therapeutic category, as of March 2012
  • Number of new clinical trials registered in Bulgaria and change (%), 2008-2014
  • Breakdown of open clinical trials in Bulgaria (%), by phase, as of March 2012
  • Number of open clinical trials in Bulgaria (%), by therapeutic category, as of March 2012
  • Number of new clinical trials registered in Slovakia and change (%), 2000-2014
  • Breakdown of open clinical trials in Slovakia (%), by phase, as of March 2012
  • Number of open clinical trials in Slovakia (%), by therapeutic category, as of March 2012
  • Average time of clinical trials registration in CE region, 2010
  • Relative cost of conducting clinical research in Poland, the Czech Republic and Hungary in comparison with selected other countries, 2008
  • The potential for clinical studies in Poland, the Czech Republic and Hungary in comparison to selected other countries, 2010
  • Number of clinical inspections carried out by the FDA in CE countries analysed, 1988-2011
  • Results of inspections of clinical trials conducted by FDA in CE countries analysed, 1988-2011
  • Deficiencies identified by the FDA during inspections of clinical trials conducted in CE countries analysed, 1988-2011
  • Number of clinical investigator inspections carried out in Poland, 1988-2011
  • Results of inspections of clinical trials conducted by FDA in Poland, 1988-2011
  • Deficiencies identified during inspections of clinical trials conducted in Poland by the FDA, 1988-2011
  • Number of clinical investigator inspections carried out in Hungary, 1988-2011
  • Results of inspections of clinical trials conducted by FDA in Hungary, 1988-2011
  • Deficiencies identified during inspections of clinical trials conducted in Hungary by the FDA, 1988-2011
  • Number of clinical investigator inspections carried out in the Czech Republic, 1988-2011
  • Results of inspections of clinical trials conducted by FDA in the Czech Republic, 1998-2011
  • Deficiencies identified during inspections of clinical trials conducted in the Czech Republic by the FDA, 1988-2011
  • Number of clinical investigator inspections carried out in Romania, 1988-2011
  • Results of inspections of clinical trials conducted by FDA in Romania, 1988-2011
  • Deficiencies identified during inspections of clinical trials conducted in Romania by the FDA, 1988-2011
  • Number of clinical investigator inspections carried out in Bulgaria, 1988-2011
  • Results of inspections of clinical trials conducted by FDA in Bulgaria, 1988-2011
  • Deficiencies identified during inspections of clinical trials conducted in Bulgaria by the FDA, 1988-2011
  • Leading 10 sponsors of clinical trials in the CE countries (number of trials), as of March 2012
  • Breakdown of Roche clinical trials in the CE countries analysed, as of March 2012
  • Breakdown of Roche clinical trials in the CE countries analysed, by therapeutic category, as of March 2012
  • Roche Pharmaceuticals spending on research and development (CHF m), y-o-y change and its share as a proportion of the company's sales (%), 2004-2011
  • Breakdown of Pfizer clinical trials in the CE countries analysed, as of March 2012
  • Breakdown of Pfizer clinical trials in the CE countries analysed, by therapeutic category, as of March 2012
  • Pfizer spending on research and development ($ m), y-o-y change and its share as a proportion of the company's revenues (%), 2004-2011
  • Breakdown of GSK clinical trials in the CE countries analysed, as of March 2012
  • Breakdown of GSK clinical trials in the CE countries analysed, by therapeutic category, as of March 2012
  • GlaxoSmithKline spending on research and development (£ m), y-o-y change and its share as a proportion of the company's revenues (%), 2001-2011
  • Breakdown of Novartis clinical trials in the CE countries analysed, as of March 2012
  • Breakdown of Novartis clinical trials in the CE countries analysed, by therapeutic category, as of March 2012
  • Novartis' spending on research and development ($ m), y-o-y change and its share as a proportion of the company's net sales (%), 2004-2011
  • Breakdown of Eli Lilly clinical trials in the CE countries analysed, as of March 2012
  • Breakdown of Eli Lilly clinical trials in the CE countries analysed, by therapeutic category, as of March 2012
  • Eli Lilly spending on research and development ($ m), y-o-y change and its share as a proportion of the company's revenues (%), 2002-2011
  • Breakdown of Bristol-Myers Squibb clinical trials in the CE countries analysed, as of March 2012
  • Breakdown of Bristol-Myers Squibb clinical trials in the CE countries analysed, by therapeutic category, as of March 2012
  • Bristol-Myers Squibb spending on research and development ($ m), y-o-y change and its share as a proportion of the company's revenues (%), 2002-2011
  • Breakdown of AstraZeneca clinical trials in the CE countries analysed, as of March 2012
  • Breakdown of AstraZeneca clinical trials in the CE countries analysed, by therapeutic category, as of March 2012
  • AstraZeneca spending on research and development ($ m), y-o-y change and its share as a proportion of the company's revenues (%), 2004-2011
  • Breakdown of Johnson & Johnson clinical trials in the CE countries analysed, by country, as of March 2012
  • Breakdown of Johnson & Johnson clinical trials in the CE countries analysed, by categories, as of March 2012
  • Johnson & Johnson spending on research and development ($ m), y-o-y change and its share as a proportion of the company's sales (%), 2002-2011
  • Breakdown of Boehringer Ingelheim clinical trials in the CE countries analysed, as of March 2012
  • Breakdown of Boehringer Ingelheim clinical trials in the CE countries analysed, by therapeutic category, March 2012
  • Boehringer Ingelheim spending on research and development (€ m), y-o-y change and its share as a proportion of the company's sales (%), 2002-2010
  • Breakdown of Amgen clinical trials in the CE countries analysed, as of March 2012
  • Breakdown of Amgen clinical trials in the CE countries analysed, by therapeutic category, as of March 2012
  • Amgen spending on research and development ($ m), y-o-y change and its share as a proportion of the company's sales (%), 2002-2010
  • Covance net revenue ($ m) and change (%), 2006-2011
  • Icon gross revenue ($ m) and change (%), 2006-H1 2011
  • Parexel service revenues by segment ($ m), 2008-2011
  • Breakdown of Altiora clinical trials (%), by phase, 2001-2010
  • Breakdown of Altiora clinical trials (%), by therapeutic category, 2001-2010
  • Breakdown of ProVal clinical trials (%), by therapeutic category, 1991-2012
  • BiTrial revenue and net profit (€ m), 2009-2010
  • Argint International revenues and net profit (€ m) in Hungary, 2010
  • Trial Masters' revenues and net profit (€ m), 2009-2010
  • Corruption Perception Index in the CE countries analysed, 2001-2011

List of tables

  • Examples of partnerships established between top pharmaceutical concerns and CROs, 2010-2012
  • Estimated structure of clinical trials value in CEE/CIS regions (%), 2010
  • CEE pharmaceutical companies in EU Industrial R&D Investment Scoreboard, by rank and value of R&D investments (€ m), 2005-2010
  • Clinical portfolio of Gedeon Richter, 2010
  • Number of clinical trials conducted in CE countries analysed, 2012
  • Key legal acts regulating the conduct of clinical trials in CE countries analysed, 2012
  • Rules of conduct for ethics committees in CE countries analysed, 2012
  • Registration of clinical trials in selected CEE countries, 2012
  • Number of clinical trial sites in Poland, the Czech Republic and Hungary in comparison with selected other countries, 2008
  • Patient recruitment per site in a non-metastatic renal carcinoma study in Poland and the Czech Republic in comparison with selected other countries, 2009
  • Patient recruitment per site in acute heart failure and renal impairment with volume overload study in Poland and Romania in comparison with selected other countries, 2009
  • CRF quality per site in a renal carcinoma study in Poland and the Czech Republic in comparison with selected other countries
  • CRF quality per site in a heart failure study in Poland, the Czech Republic, Hungary and Romania in comparison with selected other countries
  • Conducting clinical trials in Bulgaria and Romania in comparison with Russia and Ukraine, 2009
  • Breakdown of Roche clinical trials in the CE countries analysed, by phase, as of March 2012
  • Selected Roche clinical trials carried out in CE countries, as of March 2012
  • Breakdown of Pfizer clinical trials in the CE countries analysed, by phase, as of March 2012
  • Selected Pfizer clinical trials carried out in CE countries, as of March 2012
  • Breakdown of GSK clinical trials in the CE countries analysed, by phase, as of March 2012
  • Selected GlaxoSmithKline clinical trials carried out in CE countries, as of March 2012
  • Breakdown of Novartis clinical trials in the CE countries analysed, by phase, as of March 2012
  • Selected Novartis clinical trials carried out in CE countries, as of March 2012
  • Breakdown of Eli Lilly clinical trials in the CE countries analysed, by phase, as of March 2012
  • Selected Eli Lilly clinical trials carried out in CE countries, as of March 2012
  • Breakdown of Bristol-Myers Squibb clinical trials in the CE countries analysed, by phase, as of March 2012
  • Selected Bristol-Myers Squibb clinical trials carried out in CE countries, as of March 2012
  • Breakdown of AstraZeneca clinical trials in the CE countries analysed, by phase, as of March 2012
  • Selected AstraZeneca clinical trials carried out in CE countries, as of March 2012
  • Breakdown of Johnson & Johnson clinical trials in the CE countries analysed, by phase, as of March 2012
  • Selected Johnson & Johnson clinical trials carried out in CE countries, as of March 2012
  • Breakdown of Boehringer Ingelheim clinical trials in the CE countries analysed, by phase, as of March 2012
  • Selected Boehringer Ingelheim clinical trials carried out in CE countries, as of March 2012
  • Breakdown of Amgen clinical trials in the CE countries analysed, by phase, as of March 2012
  • Selected Amgen clinical trials carried out in CE countries, as of March 2012
  • Selected largest CROs operating in the clinical trials market in CE countries analysed, 2012
  • Quintiles revenues and net profit (€ m) in selected CE countries analysed, 2009-2010 or H1 2011
  • Covance revenue and net profit (€ m) in selected CE countries analysed, 2009-2010
  • Information on PPD presence in selected CE countries analysed, 2012
  • PPD revenue and net profit (€ m) in selected CE countries analysed, 2009-2010 or H1 2011
  • Icon revenues and net profit (€ m) in selected CE countries analysed, 2009-2010
  • Parexel revenue and net profit (€ m) in selected CE countries analysed, 2009-2010 or H1 2011
  • Premier Research revenue and net profit (€ m) in selected CE countries analysed, 2009-2010 or H1 2011
  • PSI revenue and net profit (€ m) in selected CE countries analysed, 2009-2010 or H1 2011
  • Sample of recent trials conducted by GCT, 2012
  • Statistical figures of BiTrial CRO activity, 2012
  • Population of the CE countries analysed ('000 people), 2006-2011
  • Percentage of population aged 0-14 years in the CE countries analysed, 2006-2010
  • Percentage of population aged 65 or over in the CE countries analysed, 2006-2010
  • Forecast of population in CE countries analysed ('000 people), 2015-2035
  • Crude death rate in the CE countries analysed, 2006-2010
  • Number of diseases of circulatory system in CE countries analysed, 2006-2010
  • Number of ischaemic heart diseases in CE countries analysed, 2006-2010
  • Number of cerebrovascular diseases in CE countries analysed, 2006-2010
  • Number of cancer cases in CE countries analysed, 2006-2010
  • Number of deaths caused by cancer in CE countries analysed, 2006-2010
  • Number of trachea, bronchus and lung cancer in CE countries analysed, 2006-2010
  • Number of deaths caused by trachea, bronchus and lung cancer in CE countries analysed, 2006-2010
  • Percentage of smokers in CE countries analysed (%), 2012
  • Number of female breast cancer in CE countries analysed, 2006-2010
  • Number of deaths caused by malignant neoplasm female breast cancer in CE countries analysed, 2006-2010
  • Number of deaths caused by the respiratory system diseases in selected CE countries analysed, 2006-2010
  • Number of deaths caused by the bronchitis/emphysema/asthma in CE countries analysed, 2006-2010
  • Number of deaths caused by the digestive system diseases in CE countries analysed, 2006-2010
  • Diabetes prevalence in selected CE countries analysed (%), 2006-2010
  • Number of deaths caused by diabetes in CE countries analysed, 2006-2010
  • Number of deaths caused by blood and blood-forming organs diseases in CE countries analysed, 2006-2010
  • Mental disorders in selected CE countries analysed (%), 2006-2010
  • Number of deaths caused by mental disorder/diseases of nervous system/sense organs in CE countries analysed, 2006-2010
  • Number of deaths caused by genitourinary system diseases in CE countries analysed, 2006-2010
  • Number of practising physicians in the CE countries analysed, 2001-2009
  • Number of hospitals in CE countries analysed, 2006-2009
  • Number of acute (short-stay) hospitals in CE countries analysed, 2006-2009
  • Number of hospital beds in CE countries analysed, 2006-2009 or 2010
  • Number of acute care hospital beds in CE countries analysed, 2006-2009 or 2010
  • Documentation required for approval of a clinical trial on a human pharmaceutical in Poland, 2012
  • Documents provided with the application for a Bioethics Committee opinion on a clinical trial, 2012
  • Minimum guaranteed sum of civil liability cover for researchers and sponsors of clinical trials in Poland, 2010
  • List of legal acts regulating clinical trials in Hungary, 2012
  • Documentation required for approval of a clinical trial on a human pharmaceutical in Hungary, 2012
  • Types of application procedure for clinical trials in Czech Republic, 2012
  • Documentation required for the approval/notification of a clinical trial on a human pharmaceutical in Czech Republic, 2012
  • Fees for filing applications and other fees connected with clinical trials in Czech Republic, 2012
  • Documentation required for ethics committees (multi-centre and local) in Czech Republic, 2012
  • List of the most important legal acts regulating clinical trials implemented in Romania, 2012
  • Documentation required for approval of a clinical trial on a human pharmaceutical in Romania, 2012
  • Charges for filing applications for clinical trial registration in Romania, 2012
  • Documentation required for approval of a clinical trial on a human pharmaceutical in Bulgaria, 2012
  • Fees for clinical trials in Bulgaria, 2012
  • Changes in clinical trials procedures included in Act No. 362/2011 on medicines and medical devices and amendments to related acts in Slovakia, 2012
  • Documentation required for approval of a clinical trial on a human pharmaceutical in Slovakia, 2012
  • Duration of approval of clinical trials applications in Slovakia, 2010
Show More
Pricing
Get Notified
Email me when related reports are published